mProX™ Human FGL1 Stable Cell Line

Pan, Zhiyong. et al. "Increased FGL1 Expression Predicts Poor Prognosis and Promotes EMT in Head and Neck Squamous Cell Carcinoma." Biochemical genetics, 2023.
Fibrinogen-like protein 1 (FGL1) is secreted by the liver and plays a role in proliferation and metabolism. It is often abnormally expressed in human malignancies, but its role in head and neck squamous cell carcinoma (HNSCC) is not well-understood. In this study, the authors analyzed FGL1 expression in HNSCC using the TCGA database and observed its impact on patient survival. They also conducted cell-based and in vivo experiments to investigate the role of FGL1 in HNSCC. Results showed that FGL1 was highly expressed in HNSCC and correlated with a poor prognosis. Knockdown of FGL1 inhibited the proliferation and invasion of HNSCC cells, and mechanistic analysis revealed that FGL1 induced an epithelial-mesenchymal transition (EMT) phenotype, promoting the malignant progression of HNSCC. In summary, the authors' findings suggest that FGL1, an oncogene, may represent a potential therapeutic target for HNSCC treatment.
Pan, Zhiyong. et al. "Increased FGL1 Expression Predicts Poor Prognosis and Promotes EMT in Head and Neck Squamous Cell Carcinoma." Biochemical genetics, 2023.
Pubmed: 37843652   DOI: 10.1007/s10528-023-10545-z

Garman, Bradley. et al. "Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands." Frontiers in immunology, 2023.
The critical role of immune cell expression profiling from patient samples in the development of successful immuno-oncology agents cannot be understated. Understanding the mechanism-of-action, identifying predictive exploratory biomarkers, and guiding treatment selection and combination therapy strategies are all made possible through this profiling. Recently, clinical success has been demonstrated by targeting LAG-3, an inhibitory immune checkpoint that suppresses antitumor T-cell responses, in combination with PD-1. In this study, the authors aimed to identify human immune cell subsets expressing LAG-3 and its ligands, characterize their marker expression profiles, and investigate any potential correlation with clinical outcomes of immuno-oncology therapies.
Garman, Bradley. et al. "Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands." Frontiers in immunology, 2023.
Pubmed: 37795090   DOI: 10.3389/fimmu.2023.1151748